Abstract
Allergic contact dermatitis (ACD) is triggered by an aberrant hyperinflammatory immune response to innocuous chemical compounds and ranks as the world's most prevalent occupational skin condition. Although a variety of immune effector cells are activated during ACD, regulatory T (Treg) cells are crucial in controlling the resulting inflammation. Insulin-like growth factor-1 (IGF-1) regulates cell proliferation and differentiation and accelerates wound healing and regeneration in several organs including the skin. Recently IGF-1 has also been implicated in protection from autoimmune inflammation by expansion of Treg cells. Here, we demonstrate that ectopic expression of IGF-1 in mouse skin suppresses ACD in a Treg cell-specific manner, increasing the number of Foxp3+ Treg cells in the affected area and stimulating lymphocyte production of the anti-inflammatory cytokine interleukin 10. Similar therapeutic effects can be achieved with systemic or topical delivery of IGF-1, implicating this growth factor as a promising new therapeutic option for the treatment of ACD.
Original language | English |
---|---|
Pages (from-to) | 977-985 |
Number of pages | 9 |
Journal | DMM Disease Models and Mechanisms |
Volume | 7 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- Atopic dermatitis
- Contact hypersensitivity
- Insulin-like growth factor-1
- Regulatory T cells
- Treg
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine (miscellaneous)
- Immunology and Microbiology (miscellaneous)
- Neuroscience (miscellaneous)
- Medicine(all)